This was a prospective, randomized, open-label, blinded end point (PROBE), 30 parallel group study with two treatment arms. A total of 160 outpatients aged 61–75 years entered a 2-week wash-out period ...
COYA 303 is an investigational biologic combination of COYA 301, Coya’s low-dose interleukin 2 (LD IL-2) and a GLP-1 receptor agonist (GLP-1RA), designed to deliver a multi-targeted immunomodulatory ...
Sildenafil is an orally active selective type 5 phosphodiesterase (PDE) inhibitor, and has proven to be an effective agent for the treatment of male ED. Sildenafil inhibits the breakdown of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback